YYÜ GCRIS Basic veritabanının içerik oluşturulması ve kurulumu Research Ecosystems (https://www.researchecosystems.com) tarafından devam etmektedir. Bu süreçte gördüğünüz verilerde eksikler olabilir.
 

Seropositivity Rates of Hbsag, Anti-Hcv, Anti-Hiv and Vdrl in Blood Donors in Eastern Turkey

dc.authorscopusid 6601985981
dc.authorscopusid 8518945300
dc.authorscopusid 8930720100
dc.authorscopusid 6701669939
dc.authorscopusid 7005791514
dc.contributor.author Dilek, I.
dc.contributor.author Demir, C.
dc.contributor.author Bay, A.
dc.contributor.author Akdeniz, H.
dc.contributor.author Öner, A.F.
dc.date.accessioned 2025-05-10T17:51:21Z
dc.date.available 2025-05-10T17:51:21Z
dc.date.issued 2007
dc.department T.C. Van Yüzüncü Yıl Üniversitesi en_US
dc.department-temp Dilek I., Department of Hematology, Yüzüncü Yil University, Faculty of Medicine, Van, Turkey; Demir C., Department of Hematology, Yüzüncü Yil University, Faculty of Medicine, Van, Turkey; Bay A., Department of Pediatric Hematology, Yüzüncü Yil University, Faculty of Medicine, Van, Turkey; Akdeniz H., Department of Infection Disease, Yüzüncü Yil University, Faculty of Medicine, Van, Turkey; Öner A.F., Department of Pediatric Hematology, Yüzüncü Yil University, Faculty of Medicine, Van, Turkey en_US
dc.description.abstract Infections caused by hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency viruses (HIV) remain the leading most important health problems worldwide. Screening tests such as HBsAs, anti-HCV, anti-HIV and VDRL are mandatory tests to look at before transfusion of blood or blood components. In this study, donors who applied to our Blood Center in a nine-year period were retrospectively evaluated with respect to HBsAs, anti-HCV, anti-HIV and syphilis seroprevalence. HBsAg, anti-HCV and anti-HIV were examined by microparticle ELISA system, and syphilis antibodies were screened by a syphilis test device. Of the total 39,002 individuals, 16,601 (42%) were females and 22,401 (58%) were males. HBsAg positivity was found in 2.55%, anti-HCV in 0.17%, anti-HIV in 0.036%, and VDRL in 0.057% of overall donors. As a result, HBsAg, anti-HCV, anti-HIV and VDRL seropositivity rates in donors living in our region were found lower than those in many regions of Turkey. Nevertheless, because there is no screening method to reduce the risk resulting from transfusion to zero, it appears that it is essential to adopt strict criteria in the selection of donors and to avoid unnecessary transfusion. © Turkish Society of Hematology. en_US
dc.identifier.endpage 7 en_US
dc.identifier.issn 1300-7777
dc.identifier.issue 1 en_US
dc.identifier.scopus 2-s2.0-34547841489
dc.identifier.scopusquality Q3
dc.identifier.startpage 4 en_US
dc.identifier.trdizinid 75538
dc.identifier.uri https://hdl.handle.net/20.500.14720/18094
dc.identifier.volume 24 en_US
dc.identifier.wosquality Q3
dc.language.iso en en_US
dc.relation.ispartof Turkish Journal of Hematology en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Anti-Hcv en_US
dc.subject Anti-Hiv en_US
dc.subject Blood Donors en_US
dc.subject Hbsag en_US
dc.subject Vdrl Seroprevalence en_US
dc.title Seropositivity Rates of Hbsag, Anti-Hcv, Anti-Hiv and Vdrl in Blood Donors in Eastern Turkey en_US
dc.type Article en_US

Files